Next Article in Journal
Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age
Previous Article in Journal
Factors Associated with Timely First-Dose Pentavalent and Measles–Rubella Vaccination: A Cross-Sectional Study in East New Britain, Papua New Guinea
Previous Article in Special Issue
Manufacturing and Financial Evaluation of Peptide-Based Neoantigen Cancer Vaccines for Triple-Negative Breast Cancer in the United Kingdom: Opportunities and Challenges
 
 
Article

Article Versions Notes

Vaccines 2025, 13(2), 157; https://doi.org/10.3390/vaccines13020157
Action Date Notes Link
article xml file uploaded 5 February 2025 10:18 CET Original file -
article xml uploaded. 5 February 2025 10:18 CET Update https://www.mdpi.com/2076-393X/13/2/157/xml
article pdf uploaded. 5 February 2025 10:18 CET Version of Record https://www.mdpi.com/2076-393X/13/2/157/pdf
article html file updated 5 February 2025 10:20 CET Original file https://www.mdpi.com/2076-393X/13/2/157/html
Back to TopTop